Akili Inc (AKLI)

$0.5751

+0.03

(+4.58%)▲

Live

Insights on Akili Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 113.0K → 114.0K (in $), with an average increase of 0.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -66.36M → -11.75M (in $), with an average increase of 148.3% per quarter

  • Vs TXG

    In the last 1 year, 10x Genomics Inc has given 43.0% return, outperforming this stock by 120.6%

Performance

  • $0.55
    $0.66
    $0.58
    downward going graph

    5.1%

    Downside

    Day's Volatility :16.08%

    Upside

    11.57%

    downward going graph
  • $0.53
    $2.76
    $0.58
    downward going graph

    9.45%

    Downside

    52 Weeks Volatility :80.97%

    Upside

    78.99%

    downward going graph

Returns

PeriodAkili IncIndex (Russel 2000)
3 Months
-52.18%
0.0%
6 Months
-66.26%
2.0%
1 Year
-78.85%
5.3%
3 Years
-94.5%
19.9%

Highlights

Market Capitalization
77.4M
Book Value
$1.06
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.02
PE Ratio
49.5
Wall Street Target Price
4.0
Profit Margin
940.71%
Operating Margin TTM
-19205.95%
Return On Assets TTM
-60.57%
Return On Equity TTM
7.28%
Revenue TTM
420.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
78.10000000000001%
Gross Profit TTM
-118.0K
EBITDA
-80.4M
Diluted Eps TTM
0.02
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.77
EPS Estimate Next Year
-0.58
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Akili Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 595.53%

Current $0.58
Target $4.00

Company Financials

FY19Y/Y Change
Revenue
20.0M
-
Net Income
-20.6M
-
Net Profit Margin
-103.24%
-
FY20Y/Y Change
Revenue
3.9M
↓ 80.29%
Net Income
-25.6M
↑ 24.29%
Net Profit Margin
-651.08%
↓ 547.84%
FY22Y/Y Change
Revenue
323.0K
-
Net Income
-19.0M
-
Net Profit Margin
-5.9K%
-
Q2 FY22Q/Q Change
Revenue
64.0K
-
Net Income
-1.7M
↓ 58.48%
Net Profit Margin
-2.7K%
-
Q3 FY22Q/Q Change
Revenue
82.0K
↑ 28.13%
Net Income
53.2M
↓ 3170.04%
Net Profit Margin
64.9K%
↑ 67631.4%
Q4 FY22Q/Q Change
Revenue
241.0K
↑ 193.9%
Net Income
-66.4M
↓ 224.66%
Net Profit Margin
-27.5K%
↓ 92459.19%
Q1 FY23Q/Q Change
Revenue
113.0K
↓ 53.11%
Net Income
-20.7M
↓ 68.79%
Net Profit Margin
-18.3K%
↑ 9208.92%
Q2 FY23Q/Q Change
Revenue
114.0K
↑ 0.88%
Net Income
-11.8M
↓ 43.22%
Net Profit Margin
-10.3K%
↑ 8013.41%
FY19Y/Y Change
Total Assets
43.5M
-
Total Liabilities
125.8M
-
FY20Y/Y Change
Total Assets
20.2M
↓ 53.65%
Total Liabilities
125.1M
↓ 0.56%
FY21Y/Y Change
Total Assets
251.2M
↑ 1144.68%
Total Liabilities
9.7M
↓ 92.25%
FY22Y/Y Change
Total Assets
144.6M
↓ 42.45%
Total Liabilities
33.9M
↑ 249.62%
Q1 FY22Q/Q Change
Total Assets
250.8M
↓ 0.17%
Total Liabilities
13.4M
↑ 38.78%
Q2 FY22Q/Q Change
Total Assets
251.0M
↑ 0.11%
Total Liabilities
15.5M
↑ 14.91%
Q3 FY22Q/Q Change
Total Assets
165.0M
↓ 34.26%
Total Liabilities
41.2M
↑ 166.37%
Q4 FY22Q/Q Change
Total Assets
144.6M
↓ 12.41%
Total Liabilities
33.9M
↓ 17.7%
Q1 FY23Q/Q Change
Total Assets
124.6M
↓ 13.81%
Total Liabilities
32.2M
↓ 5.08%
Q2 FY23Q/Q Change
Total Assets
111.5M
↓ 10.54%
Total Liabilities
28.5M
↓ 11.37%
FY19Y/Y Change
Operating Cash Flow
-29.4M
-
Investing Cash Flow
-461.0K
-
Financing Cash Flow
4.9M
-
FY20Y/Y Change
Operating Cash Flow
-24.6M
↓ 16.44%
Investing Cash Flow
-116.0K
↓ 74.84%
Financing Cash Flow
2.0M
↓ 59.54%
FY21Y/Y Change
Operating Cash Flow
-54.0M
↑ 119.88%
Investing Cash Flow
-492.0K
↑ 324.14%
Financing Cash Flow
112.8M
↑ 5547.9%
FY22Y/Y Change
Operating Cash Flow
-83.5M
↑ 54.72%
Investing Cash Flow
-81.2M
↑ 16407.32%
Financing Cash Flow
141.9M
↑ 25.78%
Q1 FY22Q/Q Change
Operating Cash Flow
-358.2K
↓ 98.02%
Investing Cash Flow
-15.0M
↑ 124766.67%
Financing Cash Flow
64.0K
↓ 45.76%
Q2 FY22Q/Q Change
Operating Cash Flow
-174.9K
↓ 51.16%
Investing Cash Flow
10.0M
↓ 166.72%
Financing Cash Flow
250.0K
↑ 290.63%
Q3 FY22Q/Q Change
Operating Cash Flow
-60.9M
↑ 34698.07%
Investing Cash Flow
-61.6M
↓ 716.66%
Financing Cash Flow
-110.0M
↓ 44084.49%
Q4 FY22Q/Q Change
Operating Cash Flow
-22.1M
↓ 63.68%
Investing Cash Flow
-14.6M
↓ 76.35%
Financing Cash Flow
251.6M
↓ 328.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.1M
↓ 13.62%
Investing Cash Flow
52.9M
↓ 462.9%
Financing Cash Flow
-45.0K
↓ 100.02%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.6M
↓ 39.33%
Investing Cash Flow
-19.4M
↓ 136.6%
Financing Cash Flow
-647.0K
↑ 1337.78%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akili Inc
Akili Inc
-42.12%
-66.26%
-78.85%
-94.5%
-94.5%
R1 Rcm Inc
R1 Rcm Inc
-4.59%
7.01%
-15.37%
-3.35%
59.47%
10x Genomics Inc
10x Genomics Inc
-13.66%
-16.9%
43.83%
-66.73%
-21.61%
Veeva Systems Inc.
Veeva Systems Inc.
7.41%
14.42%
28.58%
-25.85%
94.67%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-6.21%
-15.78%
6.35%
6.35%
6.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akili Inc
Akili Inc
49.5
49.5
NA
-0.77
0.07
-0.61
0.0
1.06
R1 Rcm Inc
R1 Rcm Inc
128.18
NA
0.77
0.06
-0.02
0.02
0.0
6.55
10x Genomics Inc
10x Genomics Inc
NA
NA
NA
-1.69
-0.22
-0.11
0.0
6.76
Veeva Systems Inc.
Veeva Systems Inc.
61.02
61.02
1.27
4.18
0.15
0.05
0.0
25.85
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
19.51
19.51
NA
3.8
0.15
0.06
0.0
15.62
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akili Inc
Akili Inc
Buy
$77.4M
-94.5%
49.5
940.71%
R1 Rcm Inc
R1 Rcm Inc
Buy
$6.3B
59.47%
128.18
-3.09%
10x Genomics Inc
10x Genomics Inc
Buy
$6.3B
-21.61%
NA
-30.31%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$32.6B
94.67%
61.02
24.2%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$31.5B
6.35%
19.51
9.62%

Institutional Holdings

  • Social Capital Group LLC

    15.18%

  • Temasek Holdings Ltd.

    14.72%

  • Neuberger Berman Group LLC

    7.39%

  • Baillie Gifford & Co Limited.

    5.97%

  • Suvretta Capital Management, LLC

    4.91%

  • Comprehensive Financial Management LLC

    1.36%

Company Information

Organization
Akili Inc
Employees
111
CEO
Dr. Walter Edward Martucci Ph.D.
Industry
Healthcare

Discover More

FAQs